[Spirometry evaluation of montelukast treatment in children with bronchial asthma].
Difficulties associated with the management of asthma were the cause of using the leukotriene antagonists. There was performed a randomised group of 31 children aged 6-18 y (mean 12 yrs., 10 girls and 21 boys) with persistent asthma and poor asthma control. Montelukast was administered once daily, 5-10 mg depended of the age of the patients. This treatment was conducted for three months. Montelukast significantly improved pulmonary lung function (as measured by spirometry). Another effect of montelukast treatment was possibility the reduction beta 2-agonist use and the required dose of inhaled corticosteroids.
Jung
Anna
A
Klinika Pediatrii i Nefrologii Dzieciecej Centrainego Szpitala Klinicznego Wojskowej Akademii Medycznej w Warszawie.
Kalicki
Bolesław
B
Zuber
Janusz
J
Dadas
Ewa
E
Straz-Zebrowska
Ewa
E
D000085:Acetates / Q000627:therapeutic use*; D000293:Adolescent; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D003521:Cyclopropanes; D005260:Female; D006801:Humans; D008297:Male; D011804:Quinolines / Q000627:therapeutic use*; D013147:Spirometry; D013440:Sulfides; D016896:Treatment Outcome
D000085:Acetates; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; C093875:montelukast